This is the Drug That Could Kick Regeneron's Stock Into Gear Post author:Sam Post published:December 13, 2017 Post category:BioPharma Regeneron shares have made little headway since the disappointing launch of Praluent in 2015. Source: BioSpace You Might Also Like Prof. Inventor Of Abx464, Abivax's Lead Drug Candidate For Inducing A Functional Cure For HIV, Awarded June 15, 2017 InspireMD Announces Distribution Agreement For CGuard EPS In Taiwan June 7, 2017 OTraces Release: Beyond Liquid Biopsy: Blood Test Can Boost Cancer Detection, Diagnosis With the Tumor Microenvironment (TME), Early Validation Results Reveal (White Paper) June 15, 2017
Prof. Inventor Of Abx464, Abivax's Lead Drug Candidate For Inducing A Functional Cure For HIV, Awarded June 15, 2017
OTraces Release: Beyond Liquid Biopsy: Blood Test Can Boost Cancer Detection, Diagnosis With the Tumor Microenvironment (TME), Early Validation Results Reveal (White Paper) June 15, 2017